Daily Medication Pearl: Efgartigimod alfa-fcab (Vyvgart)
Efgartigimod alfa-fcab (Vyvgart) is a human immunoglobulin G1 antibody fragment indicated for the treatment of generalized myasthenia gravis.
Medication Pearl of the Day: Efgartigimod alfa-fcab (Vyvgart)
Indication: Efgartigimod alfa-fcab (Vyvgart)is a neonatal Fc receptor blocker indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor antibody positive.
- Dosing: The recommended dosage is 10 mg/kg administered as an intravenous infusion over 1 hour once weekly for 4 weeks.
- Dosage forms: Injection 400 mg in 20 mL (20 mg/mL) single-dose vial.
- Adverse events: Most common adverse reactions (≥ 10%) in patients treated with gMG are respiratory tract infections, headache, and urinary tract infection.
- Mechanism of action: Efgartigimod alfa-fcab is a human immunoglobulin G1 (IgG1) antibody fragment that binds to the neonatal Fc receptor, resulting in the reduction of circulating IgG.
- Manufacturer: Argenx